Cellular immunotherapy for high grade gliomas: Mathematical analysis deriving efficacious infusion rates based on patient requirements

SIAM Journal on Applied Mathematics

Volumn 70, Issue 6, 2010, Pages 1953-1976

  Kogan, Yuri ^a   Foryś, Urszula ^b   Shukron, Ofir ^a   Kronik, Natalie ^a   Agur, Zvia ^a  

^a Institute for Medical Biomathematics Isarel   (Israel)

^b UNIVERSITY OF WARSAW   (Poland)

Author keywords

Glioblastoma; Local and global stability analysis; Mathematical model; Ordinary differential equation; Steady state; T cell

Indexed keywords

GLIOBLASTOMAS; GLOBAL STABILITY ANALYSIS; LOCAL AND GLOBAL STABILITY ANALYSIS; STEADY STATE; T CELLS;

CELLS; CURING; CYTOLOGY; DYNAMICAL SYSTEMS; EQUATIONS OF STATE; IMMUNOLOGY; ORDINARY DIFFERENTIAL EQUATIONS; SYSTEM STABILITY; TUMORS;

MATHEMATICAL MODELS;

EID: 77951167386     PISSN: 00361399     EISSN: None     Source Type: Journal    
DOI: 10.1137/08073740X     Document Type: Article

References (31)

1. Z. AGUR, R. HASSIN, AND S. LEVY, Optimizing chemotherapy scheduling using local search heuristics, Oper. Res., 54 (2006), pp.829-846. (Pubitemid 44546524)
2. J. C. ARCIERO, T. L. JACKSON, AND D. E. KIRSCHNER, A mathematical model of tumor-immune evasion and si RNA treatment, Discrete Contin. Dyn. Syst. Ser. B, 4 (2004), pp.39-58. (Pubitemid 38202954)
3. A. CAPPUCCIO, M. ELISHMERENI, AND Z. AGUR, Cancer immunotherapy by interleukin-21. Potential treatment strategies evaluated in a mathematical model, Cancer Res., 66 (2006), pp.7293-7300. (Pubitemid 44197711)
4. A. CAPPUCCIO, M. ELISHMERENI, AND Z. AGUR, Optimization of Interleukin-21 immunother-apeutic strategies, J. Theoret. Biol., 248 (2007), pp.259-266.
5. C. COPPIN, Immunotherapy for renal cell cancer in the era of targeted therapy, Expert Rev. Anticancer Ther., 8 (2006), pp.907-919.
6. L. G. DE PILLIS, A. E. RADUNSKAYA, AND C. L. WISEMAN, A validated mathematical model of cell-mediated immune response to tumor growth, Can cer Res., 65 (2005), pp.7950-7958. (Pubitemid 41297274)
7. L. G. DE PILLIS, W. GU, AND A. E. RADUNSKAYA, Mixed immunotherapy and chemotherapy of tumors: Modeling, applications and biological interpretations, J. Theoret. Biol., 238 (2006), pp.841-862. (Pubitemid 43175834)
8. S. DE VLEESCHOUWER, M. RAPP, R. V. SORG, H. J. STEIGER, W. STUMMER, S. VAN GOOL, AND M. SABEL, Dendritic cell vaccination in patients with malignant gliomas: Current status and future directions, Neurosurg., 59 (2006), pp.988-1000.
9. M. E. DUDLEY, J. R. WUNDERLICH, P. F. ROBBINS et al., Cancer regression and autoimmunity in patients after clonal repopulation with anti-tumor lymphocytes, Science, 298 (2002), pp.850-854.
10. J. HALE, Asymptotic Behavior of Dissipative Systems, Amer. Math. Soc., Providence, RI, 1988.
11. E. HOOIJBERG, J. J. RUIZENDAAL, P. J. SNIJDERS, E. W. M. KUETER, J. M. M. WALBOOMERS, AND H. SPITS, Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase, J. Immunol., 165 (2000), pp.4239-4245.
12. N. N. HUNDER, H. WALLEN, J. CAO, D. W. HENDRICKS, J. Z. REILLY, AND R. RODMYRE, Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1, New Engl. J. Medicine, 358 (2008), pp.2698-2703. (Pubitemid 351860862)
13. C. H. JUNE, Principles of adoptive T cell cancer therapy, J. Clin. Inv., 117 (2007), pp.1204-1212. (Pubitemid 46718405)
14. D. KIRSCHNER AND J. C. PANETTA, Modelling immunotherapy of the tumor-immune interaction, J. Math. Biol., 37 (1998), pp.235-252.
15. P. KLEIHUES, D. N. LOUIS, AND B. W. SCHEITHAUER, Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics, Cancer Immunol. Immunother., 61 (2002), pp.215-225.
16. Y. KOGAN, U. FORYS, N. KRONIK, O. SHUKRON, AND Z. AGUR, in preparation.
17. N. KRONIK, Y. KOGAN, V. VAINSTEIN, AND Z. AGUR, Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics, Cancer Immunol. Immunother., 57 (2008), pp.425-439. (Pubitemid 50007307)
18. CAROL KRUSE, personal communication, 2007.
19. C. A. KRUSE, L. CEPEDA, B. OWENS, S. D. JOHNSON, J. STEARS, AND K. O. LILLEHEI, Treatment ofrecurrent glioma with intracavitary alloreactive cyto toxic T lymphocytes and Interleukin-2, Cancer Immunol. Immunother., 45 (1997), pp.77-87. (Pubitemid 27497682)
20. C. A. KRUSE AND D. RUBINSTEIN, Cytotoxic T-lymphcytes reactive to patient major histocom-patibility complex proteins for therapy of brain tumors, in Brain Tumor Immunotherapy, L. M. Liau, D. P. Becker, T. F. Cloughesy, and D. D. B igner, eds., Humana Press, Totowa, NJ, 2001, pp.149-170.
21. V. A. KUZNETZOV, I. A. MAKALKIN, M. A. TAYLOR, AND A. S. PERELSON, Nonlinear dynamics of immunologenic tumors: Parameters estimation and global bifurcation analysis, Bull. Math. Biol., 56 (1994), pp.295-321. (Pubitemid 124009814)
22. L. M. LIAU, R. M. PRINS, S. M. KIERTSCHER, S. K. ODESA, T. J. KREMEN, A. J. GIOVANNONE, J. LIN, D. J. CHUTE, P. S. MISCHEL, T. F. CLOUGHESY, AND M. D. ROTH, Dendritic cell vaccination in glioblastoma patients induces systemi c and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment, Clin. Cancer Res., 11 (2005), pp.5515-5525. (Pubitemid 41060828)
23. R. A. MORGAN, M. E. DUDLEY, J. R. WUNDERLICH, M. S. HUGHES, J. C. YANG, R. M. SHERRY, R. E. ROYAL, S. L. TOPALIAN, U. S. KAMMULA, N. P. RESTIFO, Z. ZHENG, A. NAHVI, C. R. DE VRIES, L. J. ROGERS-FREEZER, S. A. MAVROUKAKIS, A ND S. A. ROSENBERG, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314 (2006), pp.126-129. (Pubitemid 44547756)
24. N. BELLOMO, M. L. BERTOTTI, AND S. MOTTA, Cancer immune system competition: Modelling and bifurcation problem, in Cancer Modeling and Simulation, Chapman and Hall/CRC, London, 2003.
25. M. W. J. SCHREURS, J. A. HERMSEN, R. I. KLEIN GELTNIK, K. SCHOLTEN, A. A. T. P. BRINK, E. W. M. KUETER, M. TIJSSEN, C. J. MEIJER, B. YLSTRA, G. A. MEIJER, AND E. HOOIJBERG, Genomic stability and functional activity may be lo st in telomerase-transduced human CD8+ T lymphocytes, Blood, 106 (2005), pp.2663-2670. (Pubitemid 41510738)
26. M. W. J. SCHREURS, K. B. J. SCHOLTEN, E. W. M. KUETER, J. J. RUIZENDAAL, C. J. L. M. MEIJER, AND E. HOOIJBERG, In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones, J. Immunol., 171 (2003), pp.2912-2921.
27. H. H. STEINER, M. M. BONSANTO, P. BECKHOVE, M. BRYSCH, K. GELETNEKY, R. AHMADI, R. SCHUELE-FREYER, P. KREMER, G. RANAIE, D. MATEJIC, H. BAUER, M. KIESSLING, S. KUNZE, V. SCHIRRMACHER, AND C. HEROLD-MENDE, Antitumor vaccination of patients with glioblastoma multiforme: A pilot study to assess feasibility, safety, and clinical benefit, J. Clin. Oncol., 22 (2004), pp.4272-4281. (Pubitemid 41185148)
28. G. P. TAYLOR, S. E. HALL, S. NAVARRETE, C. A. MICHIE, R. DAVIS, A. D. WITKOVER, M. ROSSOR, M. A. NOWAK, P. RUDGE, E. MATUTES, C. R. BANGHAM, AND J. N. WEBER, Effect of Lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and antitax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy, J. Virol., 73 (1999), pp.10289-10295.
29. N. C. VERRA, A. JORRITSMA, K. WEIJER, J. J. RUIZENDAAL, A. VOORDOUW, P. WEDER, E. HOOIJBERG, T. N. SCHUMACHER, J. B. HAANEN, H. SPITS, AND R. M. LUITEN, Human telom-erase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodificient mice, Cancer Res., 64 (2004), pp.2153-2161. (Pubitemid 38339467)
30. W. D. WICK, O. O. YANG, L. COREY, AND S. G. SELF, How many human immunodeficiency virus type 1-infected target cells can a cytotoxic T-lymphocyte kill?, J. Virol., 79 (2005), pp.13579-13586. (Pubitemid 41508170)
31. M. WOLFL, private communication, 2007.